MedTrace Logo

Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic

NCT04331834 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2023-05-01

No results posted yet for this study

Summary

The investigators aim to evaluate the efficacy of pre-exposure prophylaxis with hydroxychloroquine in healthcare workers with high-risk of SARS-CoV-2 infection.

Conditions

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine with the following dosage: * day 0: 400 mg (2 tablets) * day 1: 400 mg (2 tablets) * day 2: 400 mg (2 tablets) * day 3: 400 mg (2 tablets) * weekly: 400 mg (2 tablets) for a period of six months

DRUG

Placebos

Placebo with the following dosage: * day 0: 400 mg (2 tablets) * day 1: 400 mg (2 tablets) * day 2: 400 mg (2 tablets) * day 3: 400 mg (2 tablets) * weekly: 400 mg (2 tablets) for a period of six months

Sponsors & Collaborators

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Laboratorios Rubió

    collaborator UNKNOWN

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    collaborator OTHER

  • Hospital Plató

    collaborator OTHER

  • Hospital de Granollers

    collaborator OTHER

  • Barcelona Institute for Global Health

    lead OTHER

Principal Investigators

  • Jose Muñoz Gutiérrez, MD, PhD · Barcelona Institute for Global Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-03
Primary Completion
2020-06-25
Completion
2020-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04331834 on ClinicalTrials.gov